0000950170-23-005554.txt : 20230301 0000950170-23-005554.hdr.sgml : 20230301 20230301162302 ACCESSION NUMBER: 0000950170-23-005554 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230301 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230301 DATE AS OF CHANGE: 20230301 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Organogenesis Holdings Inc. CENTRAL INDEX KEY: 0001661181 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37906 FILM NUMBER: 23693939 BUSINESS ADDRESS: STREET 1: 85 DAN ROAD CITY: CANTON STATE: MA ZIP: 02021 BUSINESS PHONE: 781-575-0775 MAIL ADDRESS: STREET 1: 85 DAN ROAD CITY: CANTON STATE: MA ZIP: 02021 FORMER COMPANY: FORMER CONFORMED NAME: Avista Healthcare Public Acquisition Corp. DATE OF NAME CHANGE: 20151215 8-K 1 orgo-20230301.htm 8-K 8-K
False000166118100016611812023-03-012023-03-01

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):March 1, 2023

 

ORGANOGENESIS HOLDINGS INC.

(Exact Name of Registrant as specified in its charter)

 

 

Delaware

001-37906

98-1329150

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

 

 

 

85 Dan Road

Canton, MA

 

02021

(Address of principal executive offices)

 

(Zip Code)

(781) 575-0775

(Registrant’s telephone number, including area code)

Not Applicable

(Registrant’s name or former address, if change since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Class A Common Stock, $0.0001 par value

 

ORGO

 

Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

On March 1, 2023, the Company announced via press release its results for the fiscal fourth quarter and year ended December 31, 2022. A copy of the Company’s press release is hereby furnished to the Commission and incorporated herein by reference as Exhibit 99.1.

The information in the press release attached as Exhibit 99.1 is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

No.

 

Description

99.1

 

Press Release dated March 1, 2023

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Organogenesis Holdings Inc.

 

 

By:

/s/ Lori Freedman

Name:

Lori Freedman

Title:

Vice President and General Counsel

 

Date: March 1, 2023

 

 EX-99 2 orgo-ex99_1.htm EX-99.1 EX-99

Exhibit 99.1

 

img36819578_0.jpg 

 

FOR IMMEDIATE RELEASE

 

Organogenesis Holdings Inc. Reports Fourth Quarter 2022and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Guidance

 

CANTON, Mass., (March 1, 2023) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2022.

 

Fourth Quarter 2022 Financial Results Summary:

 

•
Net revenue of $115.5 million for the fourth quarter of 2022, a decrease of 10% compared to net revenue of $127.9 million for the fourth quarter of 2021. Net revenue for the fourth quarter of 2022 consists of:
o
Net revenue from Advanced Wound Care products of $108.8 million, a decrease of 10% from the fourth quarter of 2021.
o
Net revenue from Surgical & Sports Medicine products of $6.7 million, a decrease of 6% from the fourth quarter of 2021.
o
Net revenue from the sale of PuraPly products of $56.8 million, a decrease of 9% from the fourth quarter of 2021.
o
Net revenue from the sale of non-PuraPly products of $58.7 million, a decrease of 10% from the fourth quarter of 2021.
•
Net income of $7.5 million for the fourth quarter of 2022, compared to a net income of $51.0 million for the fourth quarter of 2021, a decrease of $43.5 million.
•
Adjusted net income1 of $8.9 million for the fourth quarter of 2022, compared to an adjusted net income of $54.0 million for the fourth quarter of 2021, a decrease of $45.1 million.
•
Adjusted EBITDA of $14.1 million for the fourth quarter of 2022, compared to Adjusted EBITDA of $26.3 million for the fourth quarter of 2021, a decrease of $12.3 million.

 

Fiscal Year 2022 Financial Results Summary:

 

•
Net revenue of $450.9 million for the year ended December 31, 2022, a decrease of 4% compared to net revenue of $467.4 million for the year ended December 31, 2021. Net revenue for the year ended December 31, 2022 consists of:
o
Net revenue from Advanced Wound Care products of $422.2 million, a decrease of 2% year-over-year.
o
Net revenue from Surgical & Sports Medicine products of $28.7 million, a decrease of 23% year-over-year.
o
Net revenue from the sale of PuraPly products of $242.7 million, an increase of 22% year-over-year.
o
Net revenue from the sale of non-PuraPly products of $208.2 million, a decrease of 23% year-over-year.

 

 

 

•
Net income of $15.5 million for the year ended December 31, 2022, compared to a net income of $94.2 million for the year ended December 31, 2021, a decrease of $78.7 million.
•
Adjusted net income1 of $26.2 million for the year ended December 31, 2022, compared to an adjusted net income of $101.3 million for the year ended December 31, 2021, a decrease of $75.0 million.
•
Adjusted EBITDA of $49.3 million for the year ended December 31, 2022, compared to an adjusted EBITDA of $89.1 million for the year ended December 31, 2021, a decrease of $39.9 million.

 

“Fourth quarter sales results came in above the low-end of the guidance range we provided on our third quarter earnings call,” said Gary S. Gillheeney, Sr., President and Chief Executive Officer of Organogenesis. “As expected, we saw a continuation of the challenging operating environment in the physician office setting in Q4, however we delivered double-digit growth in sales of Advanced Wound Care products in the hospital outpatient setting and, excluding ReNu, NuCel and Dermagraft, our team delivered low double-digit growth in the number of accounts served – in both the hospital outpatient and physician office settings.”

 

Mr. Gillheeney, Sr. continued: “Our financial guidance reflects a moderation in net revenue growth driven primarily by the impact of published ASPs in the physician office setting. That said, we expect to deliver solid growth in the hospital outpatient setting, to increase our customer base and to drive customer and clinician adoption deeper into existing accounts again in 2023. We will continue to be a leader in the Advanced Wound Care space while improving our competitive positions in the Surgical & Sports Medicine and burn markets as we deliver on our mission to provide integrated healing solutions that substantially improve outcomes well over the overall cost of care."

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1Defined as GAAP net income adjusted to exclude the effect of amortization, restructuring charges, the recovery of certain notes receivable from related parties, the change in the fair value of the CPN earnout, loss on extinguishment of debt, write-off of certain assets, facility construction project pause, GPO settlement fee and the resulting income taxes on these items.

 

 

 

 

Fourth Quarter 2022 Financial Results:


 

 

 

Three Month Ended December 31,

 

 

Change

 

 

 

2022

 

 

2021

 

 

$

 

 

%

 

 

 

(in thousands, except for percentages)

 

 

 

 

 

 

 

Advanced Wound Care

 

$

108,836

 

 

$

120,752

 

 

$

(11,916

)

 

 

(10

%)

Surgical & Sports Medicine

 

 

6,680

 

 

 

7,106

 

 

 

(426

)

 

 

(6

%)

Net revenue

 

$

115,516

 

 

$

127,858

 

 

$

(12,342

)

 

 

(10

%)

 

Net revenue for the fourth quarter of 2022 was $115.5 million, compared to $127.9 million for the fourth quarter of 2021, a decrease of $12.3 million, or 10%. The decrease in net revenue was driven by an decrease of $11.9 million, or 10% in Advanced Wound Care products and a decrease of $0.4 million, or 6% in net revenue of Surgical & Sports Medicine products.

 

Gross profit for the fourth quarter of 2022 was $88.4 million, or 77% of net revenue, compared to $95.3 million or 75% of net revenue for the fourth quarter of 2021, a decrease of $6.9 million, or 7%.

 

Operating expenses for the fourth quarter of 2022 were $79.7 million, compared to $75.5 million for the fourth quarter of 2021, an increase of $4.2 million, or 6%. R&D expense was $11.4 million for the fourth quarter of 2022, compared to $8.3 million in the fourth quarter of 2021, an increase of $3.1 million, or 38%. Selling, general and administrative expenses were $68.3 million, compared to $67.3 million in the fourth quarter of 2021, an increase of $1.0 million, or 2%.

 

Operating income for the fourth quarter of 2022 was $8.7 million, compared to an operating income of $19.8 million for the fourth quarter of 2021, a decrease of $11.0 million.

 

Total other expense, net, for the fourth quarter of 2022 was $0.0 million, compared to $0.9 million for the fourth quarter of 2021, a decrease of $0.9 million.

 

Net income for the fourth quarter of 2022 was $7.5 million, or $0.06 per share, compared to a net income of $51.0 million, or $0.38 per share, for the fourth quarter of 2021, a decrease of $43.5 million, or 0.33 per share.

Adjusted net income of $8.9 million for the fourth quarter of 2022, compared to adjusted net income of $54.0 million for the fourth quarter of 2021, a decrease of $45.1 million, or 83%.

 

Adjusted EBITDA was $14.1 million for the fourth quarter of 2022, compared to $26.3 million for the fourth quarter of 2021, a decrease of $12.3 million, or 47%.

 

As of December 31, 2022, the Company had $103.3 million in cash, cash equivalents and restricted cash and $70.8 million in debt obligations, compared to $114.5 million in cash, cash equivalents and restricted cash and $73.6 million in debt obligations, of which $0.2 million were finance lease obligations as of December 31, 2021.

 

 

 

 

Fiscal Year 2022 Results

The following table represents net revenue by product grouping for the year ended December 31, 2022 and December 31, 2021, respectively:

 

 

Year Ended December 31,

 

 

Change

 

 

 

2022

 

 

2021

 

 

$

 

 

%

 

 

 

(in thousands, except for percentages)

 

 

 

 

 

 

 

Advanced Wound Care

 

$

422,231

 

 

$

430,237

 

 

$

(8,006

)

 

 

(2

%)

Surgical & Sports Medicine

 

 

28,662

 

 

 

37,122

 

 

 

(8,460

)

 

 

(23

%)

Net revenue

 

$

450,893

 

 

$

467,359

 

 

$

(16,466

)

 

 

(4

%)

 

Net revenue for the year ended December 31, 2022 was $450.9 million, compared to $467.4 million for the year ended December 31, 2021, a decrease of $16.5 million, or 4%. The decrease in net revenue was driven by a decrease of $8.5 million, or 23% in net revenue of Surgical & Sports Medicine products and a decrease of $8.0 million, or 2% in Advanced Wound Care products.

 

Gross profit for the year ended December 31, 2022 is $345.9 million, or 77% of net revenue, compared to $353.2 million, or 76% of net revenue, for the year ended December 31, 2021, a decrease of $7.3 million, or 2%.

 

Operating expenses for the year ended December 31, 2022 were $323.6 million, compared to $280.9 million for the year ended December 31, 2021, an increase of $42.6 million, or 15%. R&D expense was $39.8 million for the year ended December 31, 2022, compared to $30.7 million for year ended December 31, 2021, an increase of $9.0 million, or 29%. Selling, general and administrative expenses were $283.8 million for year ended December 31, 2022, compared to $250.2 million year ended December 31, 2021, an increase of $33.6 million, or 13%.

 

Operating income for the year ended December 31, 2022 was $22.3 million, compared to an operating income of $72.2 million for the year ended December 31, 2021, a decrease of $49.9 million.

 

Total other expense, net, for the year ended December 31, 2022 was $2.0 million, compared to $9.1 million for the year ended December 31, 2021, a decrease of $7.1 million.

 

Net income of $15.5 million for the year ended December 31, 2022 or $0.12 per share, compared to net income of $94.2 million, or $0.70 per share for the year ended December 31, 2021, a decrease of $78.7 million, or $0.59 per share.

 

Adjusted net income for the year ended December 31, 2022 was $26.2 million., compared to $101.3 million for the year ended December 31, 2021, a decrease of $75.0 million, or 74%.

 

Adjusted EBITDA of $49.3 million for the year ended December 31, 2022, compared to an Adjusted EBITDA of $89.1 million for the year ended December 31, 2021, a decrease of $39.9 million, or 45%.

 

 

 

Fiscal Year 2023 Guidance:

 

For the year ending December 31, 2023, the Company expects:

 

•
Net revenue between $450.0 million and $462.0 million, remaining flat to an increase of approximately 2% year-over-year, as compared to net revenue of $450.9 million for the year ended December 31, 2022.
o
The 2023 net revenue guidance range assumes:
▪
Net revenue from Advanced Wound Care products between $420.0 million and $428.0 million, a decrease of 1% to an increase of approximately 1% year-over-year as compared to net revenue of $422.2 million for the year ended December 31, 2022.
▪
Net revenue from Surgical & Sports Medicine products between $30.0 million and $34.0 million, an increase of approximately 5% to 19% year-over-year as compared to net revenue of $28.7 million for the year ended December 31, 2022.
▪
Net revenue from the sale of PuraPly products between $180.0 million and $200.0 million, representing a decrease of approximately 18% to 26% year-over-year, as compared to net revenue of $242.7 million for the year ended December 31, 2022.
•
Net income between $7.2 million and $13.9 million and adjusted net income between $12.3 million and $19.0 million.
•
EBITDA between $26.6 million and $36.1 million and Adjusted EBITDA between $36.5 million and $46.0 million.

 

 

Fourth Quarter Earnings Conference Call:

 

Financial results for the fourth fiscal quarter of 2022 will be reported after the market closes on Wednesday, March 1st. Management will host a conference call at 5:00 p.m. Eastern Time on March 1st to discuss the results of the quarter, and provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. A live webcast of the call will also be provided on the investor relations section of the Company's website at investors.organogenesis.com.

 

For those unable to participate, the webcast will be archived at investors.organogenesis.com for approximately one year.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ORGANOGENESIS HOLDINGS INC.

UNAUDITED CONSOLIDATED BALANCE SHEETS

(amounts in thousands, except share and per share data)

 

 

 

December 31,

 

 

 

2022

 

 

2021

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

102,478

 

 

$

113,929

 

Restricted cash

 

 

812

 

 

 

599

 

Accounts receivable, net

 

 

89,450

 

 

 

82,460

 

Inventory

 

 

24,783

 

 

 

25,022

 

Prepaid expenses and other current assets

 

 

5,086

 

 

 

4,969

 

Total current assets

 

 

222,609

 

 

 

226,979

 

Property and equipment, net

 

 

102,463

 

 

 

79,160

 

Intangible assets, net

 

 

20,789

 

 

 

25,673

 

Goodwill

 

 

28,772

 

 

 

28,772

 

Operating lease right-of-use assets, net

 

 

43,192

 

 

 

49,144

 

Deferred tax asset, net

 

 

30,014

 

 

 

31,994

 

Other assets

 

 

1,520

 

 

 

1,537

 

Total assets

 

$

449,359

 

 

$

443,259

 

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Current portion of deferred acquisition consideration

 

$

-

 

 

$

1,436

 

Current portion of term loan

 

 

4,538

 

 

 

2,656

 

Current portion of finance lease obligations

 

 

-

 

 

 

200

 

Current portion of operating lease obligations

 

 

11,708

 

 

 

11,785

 

Accounts payable

 

 

32,330

 

 

 

29,339

 

Accrued expenses and other current liabilities

 

 

26,447

 

 

 

37,289

 

Total current liabilities

 

 

75,023

 

 

 

82,705

 

Term loan, net of current portion

 

 

66,231

 

 

 

70,769

 

Operating lease obligations, net of current portion

 

 

41,314

 

 

 

46,893

 

Other liabilities

 

 

1,122

 

 

 

1,557

 

Total liabilities

 

 

183,690

 

 

 

201,924

 

Commitments and contingencies (Note 18)

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued

 

 

-

 

 

 

-

 

Common stock, $0.0001 par value; 400,000,000 shares authorized; 131,647,677 and 129,408,740 shares issued; 130,919,129 and 128,680,192 shares outstanding at December 31, 2022 and 2021, respectively.

 

 

13

 

 

 

13

 

Additional paid-in capital

 

 

310,957

 

 

 

302,155

 

Accumulated deficit

 

 

(45,301

)

 

 

(60,833

)

Total stockholders' equity

 

 

265,669

 

 

 

241,335

 

Total liabilities and stockholders' equity

 

$

449,359

 

 

$

443,259

 

 

 

 

ORGANOGENESIS HOLDINGS INC. UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS

(amounts in thousands, except share and per share data)

 

 

 

Three Months Ended December 31,

 

 

Year Ended December 31,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Net revenue

 

$

115,516

 

 

$

127,858

 

 

$

450,893

 

 

$

467,359

 

Cost of goods sold

 

 

27,110

 

 

 

32,597

 

 

 

105,019

 

 

 

114,199

 

Gross profit

 

 

88,406

 

 

 

95,261

 

 

 

345,874

 

 

 

353,160

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

 

68,293

 

 

 

67,250

 

 

 

283,808

 

 

 

250,200

 

Research and development

 

 

11,395

 

 

 

8,260

 

 

 

39,762

 

 

 

30,742

 

Total operating expenses

 

 

79,688

 

 

 

75,510

 

 

 

323,570

 

 

 

280,942

 

Income from operations

 

 

8,718

 

 

 

19,751

 

 

 

22,304

 

 

 

72,218

 

Other expense, net:

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

 

30

 

 

 

(853

)

 

 

(2,009

)

 

 

(7,236

)

Loss on the extinguishment of debt

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(1,883

)

Other income (expense), net

 

 

6

 

 

 

(9

)

 

 

(13

)

 

 

(13

)

Total other expense, net

 

 

36

 

 

 

(862

)

 

 

(2,022

)

 

 

(9,132

)

Net income before income taxes

 

 

8,754

 

 

 

18,889

 

 

 

20,282

 

 

 

63,086

 

Income tax (expense) benefit

 

 

(1,268

)

 

 

32,106

 

 

 

(4,750

)

 

 

31,116

 

Net income

 

$

7,486

 

 

$

50,995

 

 

$

15,532

 

 

$

94,202

 

Net income, per share:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

0.06

 

 

$

0.40

 

 

$

0.12

 

 

$

0.73

 

Diluted

 

$

0.06

 

 

$

0.38

 

 

$

0.12

 

 

$

0.70

 

Weighted-average common shares outstanding

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

130,916,950

 

 

 

128,661,435

 

 

 

130,070,231

 

 

 

128,331,022

 

Diluted

 

 

131,857,509

 

 

 

133,348,995

 

 

 

132,383,152

 

 

 

133,662,659

 

 

 

 

 

ORGANOGENESIS HOLDINGS INC. UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS

(amounts in thousands, except share and per share data)

 

 

 

Year Ended December 31,

 

 

 

2022

 

 

2021

 

 

2020

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

 

Net income

 

$

15,532

 

 

$

94,202

 

 

$

17,234

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

 

 

 

Depreciation

 

 

5,845

 

 

 

5,781

 

 

 

4,438

 

Amortization of intangible assets

 

 

4,883

 

 

 

4,949

 

 

 

3,745

 

Amortization of operating lease right-of-use assets

 

 

7,303

 

 

 

5,946

 

 

 

-

 

Non-cash interest expense

 

 

434

 

 

 

346

 

 

 

236

 

Deferred interest expense

 

 

501

 

 

 

1,493

 

 

 

2,133

 

Deferred rent expense

 

 

-

 

 

 

-

 

 

 

1,273

 

Gain on settlement of deferred acquisition consideration

 

 

-

 

 

 

-

 

 

 

(2,246

)

Deferred tax expense (benefit)

 

 

1,980

 

 

 

(31,976

)

 

 

112

 

Loss on disposal of property and equipment

 

 

4,482

 

 

 

1,407

 

 

 

201

 

Provision recorded for doubtful accounts

 

 

1,781

 

 

 

2,999

 

 

 

1,183

 

Adjustment for excess and obsolete inventories

 

 

9,648

 

 

 

12,079

 

 

 

3,050

 

Stock-based compensation

 

 

6,552

 

 

 

3,864

 

 

 

1,661

 

Loss on extinguishment of debt

 

 

-

 

 

 

1,883

 

 

 

-

 

Change in fair value of Earnout liability

 

 

-

 

 

 

(3,985

)

 

 

203

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

 

Accounts receivable

 

 

(8,770

)

 

 

(28,654

)

 

 

(17,567

)

Inventory

 

 

(9,410

)

 

 

(9,302

)

 

 

(6,700

)

Prepaid expenses and other current assets

 

 

(378

)

 

 

(34

)

 

 

(355

)

Operating leases

 

 

(7,006

)

 

 

(6,156

)

 

 

-

 

Accounts payable

 

 

3,260

 

 

 

3,847

 

 

 

(4,102

)

Accrued expenses and other current liabilities

 

 

(11,850

)

 

 

9,354

 

 

 

1,443

 

Other liabilities

 

 

72

 

 

 

(6,065

)

 

 

(476

)

Net cash provided by operating activities

 

 

24,859

 

 

 

61,978

 

 

 

5,466

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

 

Purchases of property and equipment

 

 

(33,898

)

 

 

(31,220

)

 

 

(17,678

)

Cash paid for business acquisition

 

 

-

 

 

 

-

 

 

 

(5,820

)

Net cash used in investing activities

 

 

(33,898

)

 

 

(31,220

)

 

 

(23,498

)

Cash flows from financing activities:

 

 

 

 

 

 

 

 

 

Line of credit repayments under the 2019 Credit Agreement

 

 

-

 

 

 

(10,000

)

 

 

(23,484

)

Term loan borrowings (repayments) under the 2019 Credit Agreement

 

 

-

 

 

 

(60,000

)

 

 

10,000

 

Proceeds from term loan under the 2021 Credit Agreement, net of debt discount and issuance cost

 

 

-

 

 

 

73,174

 

 

 

-

 

Term loan repayments under the 2021 Credit Agreement

 

 

(2,813

)

 

 

(938

)

 

 

-

 

Proceeds from equity financing

 

 

-

 

 

 

-

 

 

 

64,729

 

Payment of equity issuance costs

 

 

-

 

 

 

-

 

 

 

(5,656

)

Principal repayments of finance lease obligations

 

 

(200

)

 

 

(2,630

)

 

 

(2,427

)

Proceeds from the exercise of stock options

 

 

2,070

 

 

 

2,198

 

 

 

2,823

 

Payments of withholding taxes in connection with RSUs vesting

 

 

(648

)

 

 

(737

)

 

 

-

 

Payments of deferred acquisition consideration

 

 

(608

)

 

 

(483

)

 

 

(3,517

)

Payment to extinguish debt

 

 

-

 

 

 

(1,620

)

 

 

-

 

Net cash provided by (used in) financing activities

 

 

(2,199

)

 

 

(1,036

)

 

 

42,468

 

Change in cash, cash equivalents and restricted cash

 

 

(11,238

)

 

 

29,722

 

 

 

24,436

 

Cash, cash equivalents, and restricted cash, beginning of year

 

 

114,528

 

 

 

84,806

 

 

 

60,370

 

Cash, cash equivalents, and restricted cash, end of year

 

$

103,290

 

 

$

114,528

 

 

$

84,806

 

Supplemental disclosure of cash flow information:

 

 

 

 

 

 

 

 

 

Cash paid for interest

 

$

2,649

 

 

$

5,787

 

 

$

9,609

 

Cash paid for income taxes

 

$

1,201

 

 

$

607

 

 

$

61

 

Supplemental disclosure of non-cash investing and financing activities:

 

 

 

 

 

 

 

 

 

Reimbursement of offering expenses included in prepaid expenses and other current assets

 

$

-

 

 

$

-

 

 

$

1,009

 

Fair value of shares issued for business acquisition

 

$

-

 

 

$

-

 

 

$

7,986

 

Deferred acquisition consideration and earnout liability recorded for business acquisition

 

$

828

 

 

$

-

 

 

$

5,218

 

Purchases of property and equipment in accounts payable and accrued expenses

 

$

1,928

 

 

$

3,750

 

 

$

2,391

 

Right-of-use assets obtained through lease obligations

 

$

1,350

 

 

$

53,793

 

 

$

-

 

 

 

 

 

 

 

Non-GAAP Financial Measures

Our management uses financial measures that are not in accordance with generally accepted accounting principles in the United States, or GAAP, in addition to financial measures in accordance with GAAP to evaluate our operating results. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with GAAP. Our management uses Adjusted EBITDA and adjusted net income to evaluate our operating performance and trends and make planning decisions. Our management believes Adjusted EBITDA and adjusted net income help identify underlying trends in our business that could otherwise be masked by the effect of the items that we exclude. Accordingly, we believe that Adjusted EBITDA and adjusted net income provide useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and prospects, and allowing for greater transparency with respect to key financial metrics used by our management in its financial and operational decision-making.

The following table presents a reconciliation of GAAP net income to non-GAAP EBITDA and non-GAAP Adjusted EBITDA, for each of the periods presented:

 

 

Three Months Ended December 31,

 

 

Year Ended December 31,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Net income

 

$

7,486

 

 

$

50,995

 

 

$

15,532

 

 

$

94,202

 

Interest expense

 

 

(30

)

 

 

853

 

 

 

2,009

 

 

 

7,236

 

Income tax expense (benefit)

 

 

1,268

 

 

 

(32,106

)

 

 

4,750

 

 

 

(31,116

)

Depreciation

 

 

1,514

 

 

 

1,771

 

 

 

5,845

 

 

 

5,781

 

Amortization

 

 

1,221

 

 

 

1,223

 

 

 

4,883

 

 

 

4,949

 

EBITDA

 

 

11,459

 

 

 

22,736

 

 

 

33,019

 

 

 

81,052

 

Stock-based compensation expense

 

 

1,855

 

 

 

1,083

 

 

 

6,552

 

 

 

3,864

 

Restructuring charge (1)

 

 

750

 

 

 

1,828

 

 

 

2,268

 

 

 

4,704

 

Recovery of certain notes receivable from related parties (2)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(179

)

Write-off of certain assets (3)

 

 

-

 

 

 

-

 

 

 

4,200

 

 

 

1,104

 

Change in fair value of Earnout (4)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(3,985

)

Loss on extinguishment of debt (5)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1,883

 

Facility construction project pause (6)

 

 

-

 

 

 

-

 

 

 

632

 

 

 

-

 

Settlement fee (7)

 

 

-

 

 

 

700

 

 

 

2,600

 

 

 

700

 

Adjusted EBITDA

 

$

14,064

 

 

$

26,347

 

 

$

49,271

 

 

$

89,143

 
(1)
Amounts reflect employee retention and benefits as well as other exit costs associated with the Company’s restructuring activities.
(2)
Amounts reflect the collection of certain notes receivable from related parties previously reserved.
(3)
Amount in 2021 reflects the write-off of certain design and consulting fees previously capitalized related to the construction in progress at one of the Company’s Canton, Massachusetts facilities. Amount in 2022 reflects the disposal of certain equipment related to the same facility.
(4)
Amounts reflect the change in the fair value of the Earnout liability in connection with the CPN acquisition.
(5)
Amount reflects the loss recognized on the extinguishment of the 2019 Credit Agreement upon repayment in 2021.
(6)
Amount reflects the cancellation fees incurred in connection with the Company’s decision to pause one of its manufacturing facility construction projects.
(7)
Amounts reflect the fee the Company paid to a GPO to settle previously disputed GPO fees.

 

 

 

The following table presents a reconciliation of GAAP net income to non-GAAP adjusted net income, for each of the periods presented:

 

 

Three Months Ended December 31,

 

 

Year Ended December 31,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Net income

 

$

7,486

 

 

$

50,995

 

 

$

15,532

 

 

$

94,202

 

Amortization

 

 

1,221

 

 

 

1,223

 

 

 

4,883

 

 

 

4,949

 

Restructuring charge (1)

 

 

750

 

 

 

1,828

 

 

 

2,268

 

 

 

4,704

 

Recovery of certain notes receivable from related parties (2)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(179

)

Write-off of certain assets (3)

 

 

-

 

 

 

-

 

 

 

4,200

 

 

 

1,104

 

Change in fair value of Earnout (4)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(3,985

)

Loss on extinguishment of debt (5)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1,883

 

Facility construction project pause (6)

 

 

-

 

 

 

-

 

 

 

632

 

 

 

-

 

Settlement fee (7)

 

 

-

 

 

 

700.0

 

 

 

2,600

 

 

 

700.0

 

Tax on above

 

 

(527

)

 

 

(762

)

 

 

(3,898

)

 

 

(2,117

)

Adjusted net income

 

$

8,930

 

 

$

53,984

 

 

$

26,217

 

 

$

101,261

 
(1)
Amounts reflect employee retention and benefits as well as other exit costs associated with the Company’s restructuring activities.
(2)
Amounts reflect the collection of certain notes receivable from related parties previously reserved.
(3)
Amount in 2021 reflects the write-off of certain design and consulting fees previously capitalized related to the construction in progress at one of the Company’s Canton, Massachusetts facilities. Amount in 2022 reflects the disposal of certain equipment related to the same facility.
(4)
Amounts reflect the change in the fair value of the Earnout liability in connection with the CPN acquisition.
(5)
Amount reflects the loss recognized on the extinguishment of the 2019 Credit Agreement upon repayment in 2021.
(6)
Amount reflects the cancellation fees incurred in connection with the Company’s decision to pause one of its manufacturing facility construction projects.
(7)
Amounts reflect the fee the Company paid to a GPO to settle previously disputed GPO fees.

 

The following table presents a reconciliation of projected GAAP net income to projected non-GAAP EBITDA and projected non-GAAP Adjusted EBITDA included in our guidance for the year ending December 31, 2023:

 

 

 

 

 

 

Year Ended December 31,

 

 

 

 

 

 

2023L

 

2023H

 

Net income

 

 

 

 

$

7,200

 

$

13,900

 

Interest expense

 

 

 

 

 

5,200

 

 

5,200

 

Income tax expense (benefit)

 

 

 

 

 

2,900

 

 

5,700

 

Depreciation

 

 

 

 

 

6,400

 

 

6,400

 

Amortization

 

 

 

 

 

4,900

 

 

4,900

 

EBITDA

 

 

 

 

 

26,600

 

 

36,100

 

Stock-based compensation expense

 

 

 

 

 

7,800

 

 

7,800

 

Restructuring charge

 

 

 

 

 

2,100

 

 

2,100

 

Adjusted EBITDA

 

 

 

 

$

36,500

 

$

46,000

 

The following table presents a reconciliation of projected GAAP net income to projected non-GAAP adjusted net income included in our guidance for the year ending December 31, 2023:

 

 

 

 

 

Year Ended December 31,

 

 

 

 

 

 

2023L

 

2023H

 

Net income

 

 

 

 

$

7,200

 

$

13,900

 

Amortization

 

 

 

 

 

4,900

 

 

4,900

 

Restructuring charge

 

 

 

 

 

2,100

 

 

2,100

 

Tax on above

 

 

 

 

 

(1,871

)

 

(1,871

)

Adjusted net income

 

 

 

 

$

12,329

 

$

19,029

 

 

 

 

Forward-Looking Statements

 

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include statements relating to the Company’s expected revenue, adjusted net revenue, net income, adjusted net income, EBITDA, and Adjusted EBITDA for fiscal 2023 and the breakdown of expected revenue in both its Advanced Wound Care and Surgical & Sports Medicine categories as well as the estimated revenue contribution of its PuraPly products. Forward-looking statements with respect to the operations of the Company, strategies, prospects, and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the reimbursement levels for the Company’s products; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company’s products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete; (4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company may owe rebates to the federal government prospectively on certain of its products if more than a certain percentage of the product is not administered to a patient and is discarded (wasted) by providers; (6) the Company’s ability to raise funds to expand its business; (7) the Company has incurred losses in prior years and may incur losses in the future; (8) changes in applicable laws or regulations; (9) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (10) the Company’s ability to maintain production of Affinity in sufficient quantities to meet demand; (11) any resurgence of the COVID-19 pandemic and its impact, if any, on the Company’s fiscal condition and results of operations; (12) the impact of the suspension of commercialization of: (a) ReNu and NuCel in connection with the expiration of the FDA’s enforcement grace period for HCT/Ps on May 31, 2021 and (b) Dermagraft in the second quarter of 2022 pending transition of manufacturing to a new manufacturing facility or a third-party manufacturer; and (13) other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including Item 1A (Risk Factors) of the Company’s Form 10-K for the year ended December 31, 2022 and its subsequently filed periodic reports. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

 

 

 

 

 

 

 

 

 

About Organogenesis Holdings Inc.

Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com.

 

Investor Inquiries:
Westwicke Partners
Mike Piccinino, CFA
OrganoIR@westwicke.com
443-213-0500

 

Press and Media Inquiries:
Organogenesis

Lori Freedman

LFreedman@organo.com

 

 GRAPHIC 3 img36819578_0.jpg GRAPHIC begin 644 img36819578_0.jpg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end EX-101.SCH 4 orgo-20230301.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 5 orgo-20230301_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 6 orgo-20230301_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Amendment Flag Amendment Flag Entity Incorporation State Country Code Entity Incorporation, State or Country Code City Area Code City Area Code Document Period End Date Document Period End Date Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity File Number Securities Act File Number Entity Address, Address Line One Entity Address, Address Line One Entity Tax Identification Number Entity Tax Identification Number Entity Emerging Growth Company Entity Emerging Growth Company Entity Registrant Name Entity Registrant Name Pre Commencement Tender Offer Pre-commencement Tender Offer Security 12b Title Title of 12(b) Security Entity Address, State or Province Entity Address, State or Province Document Type Document Type Written Communications Written Communications Security Exchange Name Security Exchange Name Entity Central Index Key Entity Central Index Key Local Phone Number Local Phone Number Pre Commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Cover [Abstract] Cover [Abstract] Trading Symbol Trading Symbol XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information
Mar. 01, 2023
Cover [Abstract]  
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0001661181
Document Type 8-K
Document Period End Date Mar. 01, 2023
Entity Registrant Name ORGANOGENESIS HOLDINGS INC.
Entity Incorporation State Country Code DE
Entity File Number 001-37906
Entity Tax Identification Number 98-1329150
Entity Address, Address Line One 85 Dan Road
Entity Address, City or Town Canton
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02021
City Area Code (781)
Local Phone Number 575-0775
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Class A Common Stock, $0.0001 par value
Trading Symbol ORGO
Entity Emerging Growth Company false
XML 8 orgo-20230301_htm.xml IDEA: XBRL DOCUMENT 0001661181 2023-03-01 2023-03-01 false 0001661181 8-K 2023-03-01 ORGANOGENESIS HOLDINGS INC. DE 001-37906 98-1329150 85 Dan Road Canton MA 02021 (781) 575-0775 false false false false Class A Common Stock, $0.0001 par value ORGO NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://organogenesis.com/20230301/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports orgo-20230301.htm orgo-20230301.xsd orgo-20230301_lab.xml orgo-20230301_pre.xml orgo-ex99_1.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "orgo-20230301.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "orgo-20230301.htm" ] }, "labelLink": { "local": [ "orgo-20230301_lab.xml" ] }, "presentationLink": { "local": [ "orgo-20230301_pre.xml" ] }, "schema": { "local": [ "orgo-20230301.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "orgo", "nsuri": "http://organogenesis.com/20230301", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "orgo-20230301.htm", "contextRef": "C_1ff7371a-4e82-4ce4-a6f7-793528f319ca", "decimals": null, "first": true, "lang": "en-US", "name": "dei:SecurityExchangeName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://organogenesis.com/20230301/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "orgo-20230301.htm", "contextRef": "C_1ff7371a-4e82-4ce4-a6f7-793528f319ca", "decimals": null, "first": true, "lang": "en-US", "name": "dei:SecurityExchangeName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organogenesis.com/20230301/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organogenesis.com/20230301/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organogenesis.com/20230301/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organogenesis.com/20230301/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organogenesis.com/20230301/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organogenesis.com/20230301/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organogenesis.com/20230301/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organogenesis.com/20230301/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organogenesis.com/20230301/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organogenesis.com/20230301/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organogenesis.com/20230301/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organogenesis.com/20230301/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organogenesis.com/20230301/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organogenesis.com/20230301/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organogenesis.com/20230301/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organogenesis.com/20230301/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organogenesis.com/20230301/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organogenesis.com/20230301/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organogenesis.com/20230301/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organogenesis.com/20230301/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organogenesis.com/20230301/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organogenesis.com/20230301/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0000950170-23-005554-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-005554-xbrl.zip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end